Time trends in overall survival (OS) and progression-free survival (PFS) in the first-line treatment of advanced non-small-cell lung cancer (NSCLC).

被引：0
|
作者：
Rutkowski, Jacek
Saad, Everardo D.
Buyse, Marc E.
Jassem, Jacek
机构：
[1] Med Univ Gdansk, Gdansk, Poland
[2] Dendrix Res, Sao Paulo, Brazil
[3] Int Inst Drug Dev, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_supll.e20580
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20580
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer
    Hayashi, H.
    Okamoto, I.
    Morita, S.
    Taguri, M.
    Nakagawa, K.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 (06) : 1537 - 1541
  • [32] Patterns of weight change and overall survival (OS) during first-line pembrolizumab treatment in patients with non-small cell lung cancer (NSCLC)
    Li, Mingjia
    Zhao, Songzhu
    Chian, Kenneth
    Kwon, Hyunwoo
    Jones, Nicholas
    Khorasanchi, Adam
    Gauntner, Timothy
    Coss, Christopher C.
    Phelps, Mitch A.
    Spakowicz, Daniel
    Wei, Lai
    Alahmadi, Asrar
    Memmott, Regan Michelle
    Kaufman, Jacob
    He, Kai
    Shields, Peter G.
    Carbone, David Paul
    Otterson, Gregory Alan
    Presley, Carolyn J.
    Owen, Dwight Hall
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] VALUE OF PROGRESSION-FREE SURVIVAL (PFS) IN REFRACTORY NON-SMALL CELL LUNG CANCER (NSCLC): AN EXPLORATORY MODELING ANALYSIS
    Ferrufino, C. P.
    Foley, D.
    Trochlil, K.
    Munakata, J.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A447 - A447
  • [34] Progression-free survival (PFS) of first-line VEGF-targeted therapy as a prognostic parameter for overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).
    Seidel, C.
    Fenner, M.
    Reuter, C. W.
    Ganser, A.
    Gruenwald, V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [35] OVERALL SURVIVAL (OS) AND PROGRESSION FREE SURVIVAL (PFS) RESULTS FOR A RANDOMIZED PHASE 2 TRIAL OF IPILIMUMAB (IPI) AND PACLITAXEL/CARBOPLATIN (P/C) IN FIRST-LINE STAGE IIIB/IV NON-SMALL CELL LUNG CANCER (NSCLC)
    Lynch, T. J., Jr.
    Neal, J.
    Bondarenko, I.
    Luft, A.
    Serwatowski, P.
    Barlesi, F.
    Chacko, R.
    Sebastian, M.
    Cuillerot, J.
    Reck, M.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 126 - 126
  • [36] First-line treatment for advanced non-small-cell lung cancer
    Laskin, Janessa J.
    Sandler, Alan B.
    [J]. ONCOLOGY-NEW YORK, 2005, 19 (13): : 1671 - 1676
  • [37] Influence of clinical trial participation with regard to overall survival (OS) and progression-free survival (PFS) for patients with advanced breast cancer
    Kiechle, M.
    Simstich, N. S.
    Schwarz-Boeger, U. R.
    Paepke, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] Distribution of Immune Markers and Their Association with Overall Survival and Time to Progression in Non-Small-Cell Lung Cancer (NSCLC)
    Kuykendall, Andrew T.
    Khalil, Farah
    Haura, Eric
    Antonia, Scott J.
    Schabath, Matthew
    Gabrilovich, Dmitry
    Creelan, Ben
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S268 - S269
  • [39] First-Line Maintenance With Erlotinib/Bevacizumab Improves Progression-Free Survival in Advanced Lung Cancer
    不详
    [J]. ONCOLOGY-NEW YORK, 2009, 23 (02): : 182 - +
  • [40] Elevated pretreatment serum biomarkers and correlation with progression-free(PFS) and overall survival (OS) in first-line trastuzumab-treated metastatic breast cancer
    Ali, Suhail M.
    Leitzel, Kim
    Anyanwu, Uchechi
    Hou, Hui Ying
    Evans, Matthew Stephen
    Shrivastava, Vika
    Koeztler, Wolfgang
    Fuchs, Eva-Maria
    Esteva, Francisco J.
    Carney, Walter P.
    Lipton, Allan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345